Europese Unie - Nederlands - EMA (European Medicines Agency)

merck sharp & dohme b.v. - humaan papillomavirusvaccin [types 6, 11, 16, 18, 31, 33, 45, 52, 58] (recombinant, geadsorbeerd) - condylomata acuminata; papillomavirus infections; immunization; uterine cervical dysplasia - papillomavirus vaccins - gardasil 9 is geïndiceerd voor actieve immunisatie van personen vanaf de leeftijd van 9 jaar tegen de volgende hpv ziekten:premaligne laesies en kanker beïnvloedt de baarmoederhals, vulva, de vagina en de anus veroorzaakt door het hpv-vaccin typesgenital wratten (condyloma acuminata) veroorzaakt door bepaalde hpv-types. zie hoofdstuk 4. 4 en 5. 1 voor belangrijke informatie over de gegevens die deze indicaties. het gebruik van gardasil 9 moet gebeuren in overeenstemming met officiële aanbevelingen.

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

biotest pharma gmbh - humaan cytomegalovirus immunoglobuline - oplossing voor infusie - glycine (e 640) ; water voor injectie, - cytomegalovirus immunoglobulin

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

biotest pharma gmbh landsteinerstrasse 5 d-63303 dreieich (duitsland) - humaan cytomegalovirus immunoglobuline 100 e/ml - oplossing voor infusie - glycine (e 640) ; water voor injectie - cytomegalovirus immunoglobulin

Europese Unie - Nederlands - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologicals voor felidae, - cats - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Europese Unie - Nederlands - EMA (European Medicines Agency)

merial - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain) - immunologicals voor felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs and excretion;against chlamydophila felis infection to reduce clinical signs. onsets van immuniteit zijn aangetoond 1 week na de primaire vaccinatiekuur voor rhinotracheitis, calicivirus en chlamydophila felis componenten. de duur van de immuniteit is 1 jaar na de laatste (her) vaccinatie.

Europese Unie - Nederlands - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunologicals voor felidae, - cats - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

Europese Unie - Nederlands - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals voor felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Europese Unie - Nederlands - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals voor felidae, - cats - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. onsets van immuniteit zijn aangetoond een week na de primaire vaccinatiekuur voor rhinotracheitis, calicivirus, chlamydophila felis en panleucopenie componenten. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Europese Unie - Nederlands - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals voor felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

virbac sa - levend verzwakt feliene calicivirus stam f9; levend verzwakt feliene panleucopenievirus stam lr72; levend verzwakt feliene rhinotracheÏtis herpesvirus, stam fhv f2 - lyofilisaat voor suspensie voor injectie - feline panleucopenia virus / parvovirus vaccine + feline rhinotracheitis virus vaccine + feline calicivirus vaccine - katten